| 臺大學術典藏 |
2020-05-25T06:52:09Z |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
|
Yeh K.-H;Yen-Shen Lu;Hsu C.-H;Lin J.-F;Hsu C;Kuo S.-H;Li Jr. S;Cheng A.-L.; Yeh K.-H; YEN-SHEN LU; Hsu C.-H; Lin J.-F; Hsu C; Kuo S.-H; Li Jr. S; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:08Z |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
|
Ch'Ang H.-J;Wang C.-C;Cheng A.-L;Hsu C;Yen-Shen Lu;Chang M.-C;Lin J.-T;Wang H.-P;Shiah H.-S;Liu T.-W;Chang J.-Y;Whang-Peng J;Chen L.-T.; Ch'ang H.-J; Wang C.-C; Cheng A.-L; Hsu C; YEN-SHEN LU; Chang M.-C; Lin J.-T; Wang H.-P; Shiah H.-S; Liu T.-W; Chang J.-Y; Whang-Peng J; Chen L.-T. |
| 臺大學術典藏 |
2020-05-25T06:52:07Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C;Cheng A.-L;Hsu C.-H;Yen-Shen Lu;Hsu C;Yeh K.-H;Wu C.-Y;Huang C.-S;Yang C.-H.; Lin C.-C; Cheng A.-L; Hsu C.-H; YEN-SHEN LU; Hsu C; Yeh K.-H; Wu C.-Y; Huang C.-S; Yang C.-H. |
| 臺大學術典藏 |
2020-05-25T06:52:04Z |
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway
|
Chen P.-J; Cheng A.-L.; Hsieh H.-P; YEN-SHEN LU; Hsu C.-H; Hsu C; Yeh P.-Y; Cheng A.-L.;Chen P.-J;Hsieh H.-P;Yen-Shen Lu;Hsu C.-H;Hsu C;Yeh P.-Y;Chen K.-F; Chen K.-F |
| 臺大學術典藏 |
2020-05-25T06:52:04Z |
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma
|
Cheng A.-L.;Hsu C;Yen-Shen Lu;Wang D.-S;Fan H.-H;Yu S.-L;Liou J.-Y;Liang J.-D;Shen Y.-C;Ou D.-L; Ou D.-L; Shen Y.-C; Liang J.-D; Liou J.-Y; Yu S.-L; Fan H.-H; Wang D.-S; YEN-SHEN LU; Hsu C; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:03Z |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
Cheng A.-L.; Lin C.-H; Chang K.-J; Kuo W.-H; Hsu C; Lee W.-C; Liau J.-Y; Huang C.-S; Shao Y.-Y;Kuo K.-T;Hu F.-C;Yen-Shen Lu;Huang C.-S;Liau J.-Y;Lee W.-C;Hsu C;Kuo W.-H;Chang K.-J;Lin C.-H;Cheng A.-L.; Shao Y.-Y; Kuo K.-T; Hu F.-C; YEN-SHEN LU |
| 臺大學術典藏 |
2020-05-25T06:51:58Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Cheng A.-L.;Hsu C.-H;Shen Y.-C;Huang C.-C;Yen-Shen Lu;Hsiao C.-H;Lee K.-D;Hsu C;Lin Z.-Z;Shao Y.-Y; Shao Y.-Y; Lin Z.-Z; Hsu C; Lee K.-D; Hsiao C.-H; YEN-SHEN LU; Huang C.-C; Shen Y.-C; Hsu C.-H; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:51:56Z |
The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: A comparative study of the efficacy of anthracyclines and non-anthracyclines
|
Chen W.-W;Chang D.-Y;Huang S.-M;Lin C.-H;Hsu C;Lin M.-H;Huang C.-S;Yen-Shen Lu;Cheng A.-L.; Chen W.-W; Chang D.-Y; Huang S.-M; Lin C.-H; Hsu C; Lin M.-H; Huang C.-S; YEN-SHEN LU; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:38Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Chih-Hung Hsu;Cheng A.-L.;Hsu C.;Yang C.-H.;Lu Y.-S.;Lin C.-C.;Bu C.-F.;Yeh K.-H.; CHIH-HUNG HSU; Cheng A.-L.; Hsu C.; Yang C.-H.; Lu Y.-S.; Lin C.-C.; Bu C.-F.; Yeh K.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:37Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
CHIH-HUNG HSU; Wu C.-Y.; Cheng A.-L.; Lu Y.-S.;Hsu C.;Li C.-C.;Kuo S.-H.;Yeh K.-H.;Yang C.-H.;Chih-Hung Hsu;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Hsu C.; Li C.-C.; Kuo S.-H.; Yeh K.-H.; Yang C.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:35Z |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
|
Yeh K.-H.;Lu Y.-S.;Chih-Hung Hsu;Lin J.-F.;Hsu C.;Kuo S.-H.;Li Jr. S.;Cheng A.-L.; Yeh K.-H.; Lu Y.-S.; CHIH-HUNG HSU; Lin J.-F.; Hsu C.; Kuo S.-H.; Li Jr. S.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:35Z |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer
|
Shiah H.-S.;Cheng A.-L.;Hsu C.;Chih-Hung Hsu;Liu T.-W.;Chang J.-Y.;Jan C.-M.;Chao Y.;Yu W.-L.;Chuang T.-R.;Whang-Peng J.;Chen L.-T.; Shiah H.-S.; Cheng A.-L.; Hsu C.; CHIH-HUNG HSU; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2020-04-28T07:25:31Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
CHIH-HUNG HSU;Cheng A.-L.;Hsu W.-L.;Tsai Y.-C.;Hsu C.;Yang C.-H.;Yeh K.-H.;Lin C.-C.; Lin C.-C.; Yeh K.-H.; Yang C.-H.; Hsu C.; Tsai Y.-C.; Hsu W.-L.; Cheng A.-L.; CHIH-HUNG HSU |
| 臺大學術典藏 |
2020-04-28T07:25:30Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H.; CHIH-HUNG HSU; Yu C.-J.; Chang Y.-C.; Hsu C.; Yang C.-H.;Yang P.-C.;Cheng A.-L.;Lin C.-C.;CHIH-HUNG HSU;Yu C.-J.;Chang Y.-C.;Hsu C.;Lin Z.-Z.; Lin Z.-Z. |
| 臺大學術典藏 |
2020-04-28T07:25:28Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L.; Shen Y.-C.; CHIH-HUNG HSU; Chih-Hung Hsu;Shen Y.-C.;Lin Z.-Z.;Chen P.-J.;Shao Y.-Y.;Ding Y.-H.;Hsu C.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:28Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Chih-Hung Hsu;Yang T.-S.;Hsu C.;Toh H.C.;Epstein R.J.;Hsiao L.-T.;Chen P.-J.;Lin Z.-Z.;Chao T.-Y.;Cheng A.-L.; CHIH-HUNG HSU; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:27Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
Shao Y.-Y.;Lin Z.-Z.;Hsu C.;Shen Y.-C.;Chih-Hung Hsu;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; CHIH-HUNG HSU; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:25Z |
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials
|
Yang S.-H. ;Kuo Y.-H. ;Tien Y.-W. ;Hsu C. ;Chih-Hung Hsu ;Kuo S.-H. ;Cheng A.-L.; Yang S.-H.; Kuo Y.-H.; Tien Y.-W.; Hsu C.; CHIH-HUNG HSU; Kuo S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:25Z |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
Shao Y.-Y. ;Lin Z.-Z. ;Chen T.-J. ;Hsu C. ;Shen Y.-C. ;Chih-Hung Hsu ;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Shen Y.-C.; CHIH-HUNG HSU; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:14Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Yu C.-W.; Hsu C.-Y.; Chen B.-B.; Chen B.-B.;Hsu C.-Y.;Yu C.-W.;Liang P.-C.;Hsu C.;Chih-Hung Hsu;Cheng A.-L.;Shih T.T.-F.; Liang P.-C.; Hsu C.; CHIH-HUNG HSU; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-04-28T07:25:13Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.; Shao Y.-Y.;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Chih-Hung Hsu;Wang M.-J.;Cheng A.-L.;Hsu C.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; CHIH-HUNG HSU; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2020-04-28T07:25:08Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.;Chen B.-B.;Hung Y.-P.;Huang P.-H.;Shen Y.-C.;Shao Y.-Y.;Chih-Hung Hsu;Cheng A.-L.;Lee R.-C.;Chao Y.;Hsu C.; Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; CHIH-HUNG HSU; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C. |
| 臺大學術典藏 |
2020-04-27T08:45:31Z |
Recent advances in non-surgical treatment for advanced hepatocellular carcinoma
|
Hsu C.;Chia-Hsien Cheng;Cheng A.-L.; Hsu C.; CHIA-HSIEN CHENG; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-27T08:45:13Z |
Consensus development from the 5th asia-pacific primary liver cancer expert meeting (APPLE 2014)
|
Seong J.; Jia J.-D.; Han K.-H.; Cheng A.-L.; Yeo W.; Hsu C.;Chen B.-B.;Chen C.-H.;Ho M.-C.;Chia-Hsien Cheng;Kokudo N.;Murakami T.;Yeo W.;Seong J.;Jia J.-D.;Han K.-H.;Cheng A.-L.; Hsu C.; Chen B.-B.; Chen C.-H.; Ho M.-C.; CHIA-HSIEN CHENG; Kokudo N.; Murakami T. |
| 臺大學術典藏 |
2020-04-27T08:45:07Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Huang Y.-H.; Lee K.-T.; Wang C.-C.; Chau G.-Y.; Lee W.-C.; Ting C.-T.; Lee P.-H.; Wu C.-C.; Huo T.-I.; Liao L.-Y.; Huang S.-F.; Hung C.-F.; Yang S.-S.; Chen R.-C.; Chen C.-H.; Dai C.-Y.; Wang T.-E.; Su C.-W.; Wang J.-H.; Lu S.-N.;Wang J.-H.;Su C.-W.;Wang T.-E.;Dai C.-Y.;Chen C.-H.;Chen R.-C.;Yang S.-S.;Hung C.-F.;Huang S.-F.;Liao L.-Y.;Huo T.-I.;Wu C.-C.;Lee P.-H.;Ting C.-T.;Lee W.-C.;Chau G.-Y.;Wang C.-C.;Lee K.-T.;Huang Y.-H.;Ho M.-C.;Lin S.-M.;Huang G.-T.;Chen K.-Y.;Lin X.-Z.;Hwang J.-I.;Chiou Y.-Y.;Wang C.-K.;Hu J.-T.;Chen S.-C.;Liang P.-C.;Lee R.-C.;Wu D.-K.;Lin C.-Y.;Lin C.-C.;Cheng A.-L.;Hsu C.;Chao Y.;Chen L.-T.;Wang P.-M.;Wang P.-M.;Hong J.-H.;Hsu H.-C.;Chen S.-W.;Leung S.W.;Chia-Hsien Cheng;Wu J.-C.;Wu C.-Y.;Hsu Y.-C.;Hsu C.-W.;Ni Y.-H.;Lin C.-L.;Local Ablation Group, Surveillance Group, Diagnosis Group, Staging Group, Surgery Group, Tace/Tare/Hai Group, Target Therapy/Systemic Therapy Group, Radiotherapy Group, Prevention Group, Drafting Group; Lu S.-N.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; CHIA-HSIEN CHENG; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
